by Grow Up Conference | Sep 21, 2023 | Grow Opportunity, Media Partners
(Globe Newswire) Chicago and Vancouver — Green Thumb Industries Inc., a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today announced that Richard Reisin and Hannah (Buchan) Ross have been appointed to its board of directors as independent members, effective September 20, 2023.
Reisin will serve on the audit committee and Ross will serve on the audit and compensation committees of the board. The appointments bring the company’s board of directors to a total of nine members.
“We are thrilled to expand our board and welcome Richard and Hannah to the team,” said Green Thumb Founder, chairman and CEO, Ben Kovler. “Richard has extensive experience in operations, legal, finance and accounting, while Hannah brings deep expertise in branding, capital markets, investments, finance, and operations with a focus on the cannabis industry. Both individuals will bring valuable insights and perspectives to the Board, and we look forward to the positive impact they will have on the business as we prepare for the future of cannabis in the United States including a potential listing on a major U.S. exchange.”
Reisin formerly served as executive vice president and director at Carylon Corporation, a national organization of industry-leading, regional operating companies that offer a wide range of specialized services including sewer maintenance, industrial services, and water management for municipalities, utilities, and industrial companies.
Prior to that, Reisin was a CPA and director at Ostrow Reisin Berk & Abrams, Ltd., where he specialized in accounting, audit, tax, and consulting services for privately held businesses in a variety of industries including construction, distribution, broker dealers, manufacturing, and service businesses.
“I am excited to join the Board of the leading company in cannabis,” said Reisin. “The management team at Green Thumb has a proven track record of focused execution, consistently strong results, and the best balance sheet in the industry. I look forward to leveraging my experience to help the business continue to prosper.”
Ross is the COO of Edie Parker, the leading female-founded lifestyle, fashion, and cannabis brand. She oversees the growth strategy and operations of the company, including direct management of the finance, sales, and marketing functions. Since 2018, Ross has also been a Partner at Beehouse, an investment firm that has allocated over $300 million to the legal cannabis industry. Prior to that, Ross worked in the Investment Banking Division at Goldman Sachs, advising companies on equity capital markets, including IPOs, up listings, spin-offs, follow-on transactions, and mergers and acquisitions in the healthcare and consumer/retail sectors.
“Not only does Green Thumb have an impressive financial foundation, but it also has the best brand portfolio in the industry,” said Ross. “I am eager to utilize my expertise to contribute to the continued growth of the Company, which is well-positioned for success over the medium and long term.”
by Grow Up Conference | Sep 21, 2023 | Grow Opportunity, Media Partners
By John Watson, Local Journalism Initiative Reporter
Wheatland County Municipal Planning Commission (MPC) has approved the amendment of a development application for a cannabis store within the hamlet of Gleichen.
The application submitted to the county was to amend the development permit issued May 31, 2022, proposing to change the hours of operation of the store.
Prior to the approval of the change at the MPC meeting, the applicant had been approved to operate their store Monday to Sunday from 11 a.m. until 8 p.m. The approved amendment now allows the applicant to operate from 10 a.m. until 10 p.m. regularly, and until midnight on special occasions.
The license issued to the applicant by Alberta Gaming, Liquor and Cannabis (AGLC) prescribes a maximum operational period between 10 a.m. and 2 a.m. The county also noted the building in question has been renovated to meet AGLC standards.
According to county administration, all conditions of the previous development permit have been met, including all building renovations, audits, fire inspections, and confirmation of a valid license.
The original development permit which was granted to the applicant by the Subdivision and Development Appeal Board for a two-year term was scheduled to expire, April 12, 2024. The applicant had also requested the county consider the amendment application be regarded as a renewal application.
County administration agreed a future renewal application of the development permit is not required and the applicant may proceed as planned.
A letter from the applicant was circulated around the surrounding community of their planned operations, gauging support for their increased hours, to which they reported nearly 260 responses in support of their intentions.
The county, receiving 10 letters themselves regarding the applicant, were notified of nine in support, and one person expressing opposition.
Rather than including all of the letters responding to the applicant in the MPC agenda, a list was compiled and was made publicly available regarding who the responders were, their noted opinions, and where they are from.
In a message to the county, the applicant reported positive results from their business in the approximate year and a half since their license was issued to operate. This message included notation of a lack of loitering, damage to the store and surrounding area, and consistent traffic that is not a hinderance to their neighbours.
“Since the opening of the store, I have not heard a single complaint or concern from any ratepayers in the hamlet. There are still of course folks who philosophically disagree with the legalization or the use of cannabis, but there have been no complaints or concerns,” said Reeve Amber Link. “I have had gratitude expressed for the responsibility of the owner, there has been multiple community events that the owner and the store have supported and sponsored, they have also donated to different community events and initiatives within the community.”
Wheatland County MPC approved the amendment of the development application following a brief discussion, noting the success of the store and lack of complaints regarding its presence.
by Grow Up Conference | Sep 21, 2023 | Grow Opportunity, Media Partners
(Globe Newswire) Vancouver — LEEF Brands Inc., a vertical cannabis operator, is pleased to announce the successful closing of the acquisition of the Salisbury Canyon Ranch LLC., a 1,900-acre ranch located in Santa Barbara County.
Additionally, as previously announced on June 1, 2023, the company has sold a 60 per cent interest in the Ranch for $7.0 Million through an interest-free loan agreement, of which the proceeds will be used to finance the buildout and operation of one of the largest biomass cultivation sites in California. LEEF will remain the 100% owner of the state cannabis licenses and shall exclusively occupy and manage the Ranch and the cultivation operation.
“This is a monumental milestone for LEEF as the acquisition and buildout of the Ranch will enable us to fully execute our vision of building one of the largest biomass cultivation sites in California. The buildout marks a tremendous opportunity for LEEF and lays the foundation for future expansion. As a customer-service-focused company, we believe that controlling our supply chain will allow us to improve upon quality and consistency, create superior products and provide exceptional service to our clients. I would also be remiss if I didn’t mention the recent federal contemplation of rescheduling cannabis to Schedule 3. The elimination of the 280E tax on our business and on our customer’s business would have dramatic and immediate positive implications for an industry that has been plagued by high taxes, high cost of capital, lack of investment capital and lack of access to traditional financial services,” said Micah Anderson, CEO of LEEF Brands.
Kevin Wilson, Chief Financial Officer added, “Our team has devoted substantial resources to identifying areas in which we can garner operational efficiencies and increase profitability. For LEEF, our intention is to slowly build out a secure supply chain that will be strategically planted to support our specific manufacturing capabilities.”
Under the terms of the Transaction, the Company has acquired the Ranch for a purchase price of $5.48 Million with $1.1 Million due at closing. The Company separately entered into a five-year promissory note agreement with Salisbury Canyon Ranch LLC. to vendor finance $4.2 Million on which interest only payments will be made for a period of 24 months at an interest rate of 4 per cent per annum.
by Grow Up Conference | Sep 21, 2023 | Cannabis Prospect Magazine, Media Partners
by Grow Up Conference | Sep 21, 2023 | Cannabis Prospect Magazine, Media Partners
by Grow Up Conference | Sep 21, 2023 | Cannabis Prospect Magazine, Media Partners
by Grow Up Conference | Sep 21, 2023 | Cannabis Prospect Magazine, Media Partners
by Grow Up Conference | Sep 21, 2023 | Extraction Magazine, Media Partners
Here you can find a selection of cannabis scientific studies published in the latest month. Each article is correlated with a short abstract describing the purpose of the study and the main research findings.A great cannabis culture comes from great and peer reviewed sources! For this reason we believe in the importance of consulting reliable sources. Whether you are interested in a particular article don’t hesitate to read the full piece for more information.
Cannabis and Health ⎯ Best new findings
Cannabinoids for symptom management in children with cancer: A systematic review and meta‐analysis
In this systematic review are collected all the info related to the use of cannabis products in clinical applications for children with cancer. The aim of this research was collecting data about the types of cannabis used, doses, formulations, frequencies, clinical indications, routes of administration as well as the cannabinoid-linked adverse effects. From the research emerges that cannabinoids have been used mainly to face chemotherapy-induced nausea and vomiting. Among the adverse effects of cannabis use in this context there are dry mouth, dizziness and somnolence. However no serious cannabis-related adverse events were reported. Even if there is evidence of cannabis support in managing chemotherapy-related symptoms there is still a lack of a rigorous range of dosing, safety profiles and proven cannabis efficacy. More study should be done in order to fully understand the potential of this plant in treating children with cancer.
Source: https://doi.org/10.1002/cncr.34920
Among possible palliative medications to treat symptoms associated with neurological diseases, Cannabis sativa L. has a promising future. There is still lack of evidence about cannabis effectiveness to treat symptoms such as pain and nausea linked to Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, depression, etc. Nevertheless new technologies are arousing, boosting the global market of cannabis because tetrahydrocannabinol (THC) and cannabidiol (CBD) benefits have been proven in several studies. This is important research because many countries are hostile to cannabis regulation changes due to concerns regarding the possible addiction or other adverse events, and poor or uncertain effectiveness evidence.
Source: https://doi.org/10.1016/j.jtcme.2023.08.006
Epidiolex (Cannabidiol) has been approved by the FDA for the treatment of two rare and severe forms of epilepsy related diseases, namely Lennox-Gastaut syndrome (LGS) and Dravet (DS). IN addition to that cannabidiol have gained attention in terms of possible neuroprotection, anti-epilepsy, anti-inflammation, anti-anxiety, and anti-cancer agent. This article covers the synthesis of cannabidiol and its analogues as well as the promising significant activities of these molecules.
Source: https://doi.org/10.1016/j.bioorg.2023.106810
The implementation of the Cannabis Act in 2018 stated that growers have to proof that their crops are cultivated without the use of unauthorized pesticides and that there are not harmful chemicals in their final products. This study shows how the Cannabis act is providing a safer cannabis production in Canada compared to the inflorescences coming from the illegal market. The analyses are performed using an extensive multi-residue method in a combination of gas chromatography, triple quadrupole mass spectrometry for the quantification of 327 pesticides at the same time. Chlorpyrifos, imidacloprid, and myclobutanil substances were measured in illicit samples in relevant concentrations.
Source: https://doi.org/10.1186/s42238-023-00200-0
Cannabis and biological effects ⎯ Best new findings
Bisabolol is one terpene commonly found in certain strains of cannabis, sage, and chamomile that has been shown to have potential anxiolytic effects. This study shows that bisabolol increases locomotion at the highest concentration used here (0.002%) but does not affect anxiety-like behavior in zebrafish.
Source: https://journals.macewan.ca/studentresearch/article/view/2671
This study aimed to investigate the effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) and some standardized cannabis extracts (F1, F2, F3) on migration, invasion, and apoptosis of human breast cancer (MCF-7) cells. Using the colorimetric assay MTT it was evaluated the cell metabolic activity after treatment with cannabis extracts or concentrates. Other used techniques were clonogenic, and nuclear staining assays. To find out the mechanism of cannabinoids against MCF-7 cells, Western blot analysis was used. In addition to that the cell migration and invasion were evaluated using the wound healing, trans-well, and filopodia assays. The results of this study show that THC, CBD and the standardized extract F1 have great abilities for preventing cell metastasis in breast cancer in vitro experiments.
Source: https://doi.org/10.1016/j.tiv.2023.105667
A type II cannabis extract and a 1:1 blend of Δ(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space
This study shows that the antinociception induced by blended treatments of apparently equivalent composition not only differs in magnitude, but also relies on distinct engagement of spinal/DRG targets of the endocannabinoid system.The antinociceptive responses and targets engaged by blended cannabinoids are composition-specific. This study constitutes and evidence of the fact that CBD and minor cannabinoids found in cannabis products may influence THC antinociception via pharmacodynamic targets that mediate the desired analgesic actions of cannabinoids
Source:https://doi.org/10.3389/fphar.2023.1235255
Cannabis Growing and nutrition studies ⎯ Best new findings
Comparison of cannabinoids and terpenes profiles of different hemp extracts obtained from Felina and Santhica varieties cultivated in Belgium
This study reports the phytochemical composition of two different cannabis varieties. The extractions were performed both with ethanol or acidified hexane at different temperatures using pressurized solvent extraction (PSE) method. The cannabinoids content was measured using high performance liquid chromatography (HPLC) while the terpenes were measured through gas chromatography (GC). From the analyses came out that hexane extracts even if lower in overall yield contained more cannabinoids than ethanol extracts. This proves a better selectivity for hexane as an extractant. It was noticed that the extract composition became less abundant and variate rising the extraction temperature, in line with previous studies.
Source: https://hdl.handle.net/2268/305926
Although herbs have been used in wine since ancient times, there is relatively limited scientific research published on infused wines. In the present study, three different herbs (Salvia officinalis, Melissa officinalis and Cannabis sativa) were added both in must (pre-fermentation herb addition) and in stable wine (post-fermentation herb addition) from three indigenous Greek grape varieties. The results indicate that the post-fermentation addition of herbs leads to a significant increase in antioxidant activity and phenolic compounds compared to blank wine.
Source: https://doi.org/10.3390/horticulturae9090956
by Grow Up Conference | Sep 21, 2023 | Cannabis News Wire, Media Partners
- Lexaria’s IND application builds on five previous human clinical studies showing zero serious adverse effects and evidencing a reduction in resting blood pressure in test subjects
- DehydraTECH(TM)-CBD has the potential to have pronounced clinical benefits relative to the available anti-hypertensive therapeutics on the market today
- Work mostly under Lexaria’s control was completed earlier this year, including the batch manufacturing of DehydraTECH-CBD and placebo materials necessary for the IND application
- Lexaria is waiting to submit until the necessary documentation outside of their control is ready for the IND application
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track for its upcoming Investigational New Drug (“IND”) submission. The application is for the company’s planned US Phase 1b Hypertension Clinical Trial HYPER-H23-1, entitled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” looks to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM)-processed CBD in hypertensive patients.
Lexaria’s IND submission builds on five previous human clinical studies conducted from 2018 to 2022 and is integral to the successful filing and review of the submission. These studies were carried out in an aggregate total of 134 healthy and hypertensive persons and evidenced significant reductions in resting blood pressure over both acute and multi-week dosing regimens. The studies also showed zero serious adverse effects, evidencing Lexaria’s DehydraTECH-CBD’s potential to have pronounced clinical benefits relative to available anti-hypertensive therapeutics.
“That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” said Chris Bunka, CEO of Lexaria (https://cnw.fm/rG6OB).
Work mostly under Lexaria’s control was completed earlier this year, including the batch manufacturing of DehydraTECH-CBD and placebo materials necessary for the IND application. However, work outside the company’s control remains delayed, including the provision of required documentation by a materials supplier and stability testing of the material. Despite this delay, Lexaria is still progressing toward its application submission.
The company is only aware of a handful of other published research investigating whether a decrease in resting blood pressure is possible following multiple weeks of oral CBD use. Lexaria notes that none of this published research has succeeded in achieving this goal. The outcomes of the company’s previous research prove DehydraTECH-CBD’s superior power to reduce blood pressure over oral CBD formulations.
Lexaria’s DehydraTECH technology is designed for formulating and delivering lipophilic drugs and active pharmaceutical ingredients (“APIs”). DehydraTECH increases their effectiveness and improves the way these APIs enter the bloodstream. The major benefits of a DehydraTECH-enabled drug or consumer product include:
- Faster delivery time – with the effects of the product felt in minutes
- Increased bioavailability – the technology is more effective at delivering a drug or product directly to the bloodstream
- Increased brain absorption – animal testing has suggested significant improvement in the quantity of the drug delivered across the blood-brain barrier
- Improved potency – more of the ingested product is made available to the body, with lower dosages necessary for the desired result
- Reduced administration costs – lower dosages mean less overall drug costs
- Masking unwanted tastes – the technology eliminates or reduces the need for sweeteners
DehydraTECH is suitable for use with various product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, topicals and over-the-counter capsules, pills, tablets, and oral suspensions. The company’s technology is best considered an additional layer that can improve the effectiveness of existing drug offerings or planned new offerings. Lexaria’s DehydraTECH is covered by over 30 granted patents and has many more pending worldwide.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
by Grow Up Conference | Sep 21, 2023 | Cannabis News Wire, Media Partners
The California Assembly has approved a bill to legalize marijuana cafes in the state; the body sent the bill to Governor Gavin Newsom’s desk for his signature. Bill AB 374 would allow recreational cannabis dispensaries to provide customers with noncannabis drinks and foods as long as they receive approval from local authorities.
Senate lawmakers received the measure from assemblymembers, made slight amendments, and approved it in a 33 to 3 vote nearly one week ago before sending it back to the assembly for a concurrence vote. The assembly voted in favor of the amended cannabis cafe bill just a few days after receiving it from the Senate in a 48 to 7 vote, putting it on track to becoming a law if it receives Governor Newsom’s signature.
Assemblymember Matt Haney introduced the measure and envisioned it going through a relatively quick concurrence vote due to “strong bipartisan support.”
While lawmakers in the state recently concluded working on marijuana cafe legislation, California has a grey market populated with businesses that found legal workarounds to provide cannabis for on-site consumption while providing food for guests. If Newsom signs the measure into law, entrepreneurs with authorization from local governments will be able to prepare and sell nonmarijuana soft drinks and foods to customers at retail establishments.
Haney’s bill would legitimize the industry while prohibiting smoking tobacco and the sale of alcoholic beverages at marijuana cafes. It would also allow cannabis lounges to hold live performances of different varieties and sell tickets to these events.
Although microbusinesses and retailers would have the authority to sell freshly prepared drinks and foods, only retailers would be allowed to sell prepackaged food to customers, keeping the cannabis cafe rules in line with policies adopted by the California Department of Cannabis Control (DCC) in late 2022. Senate lawmakers amended the cannabis cafe bill to make it clear that it prohibits the sale of hemp-based foods and drinks at marijuana cafes by clarifying that it does not consider such products to be “noncannabis” products. The measure also states that cannabis cafes should store and display noncannabis items separately and distinctly from any cannabis products on site.
California legalized recreational cannabis in late 2016 and quickly built up the largest recreational marijuana market in the world. Cannabis retailers in the state generate billions of dollars in revenue every year, and even though marijuana sales declined last year, California‘s cannabis market had a $2.2 billion valuation in 2022.
The regulatory change allowing cannabis cafes to operate in California is likely to be copied in other jurisdictions where marijuana is legal for adult use. As a result, companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) could find themselves having to adjust to this reality in the markets where they operate.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
Recent Comments